Eli Lilly and Company said it plans to invest more than $1.2 billion to expand and modernize its Lilly del Caribe manufacturing site in Carolina, Puerto Rico. This new investment will integrate advanced technologies and expand production capacity within the existing campus.
The enhanced facility will be among those that will manufacture orforglipron, Lilly's first oral, small molecule GLP-1 receptor agonist, which the company expects to submit to global regulatory agencies for obesity by the end of this year.
The company recently shared plans to build sites in Texas and Virginia, with two additional locations to be announced in the next few months. These new sites are part of Lilly's broader efforts to expand existing U.S. manufacturing sites to increase capacity.
This facility will deploy advanced technologies in oral solid medicine manufacturing, including dock-to-dock automation and material flow, paperless manufacturing, process analytical technology and spray-dried dispersion.
Lilly estimates that the project will generate up to 1,000 construction jobs and 100 additional manufacturing positions. Construction on the expanded oral solid medicine product manufacturing facility is estimated to begin in 2026, with plans to start producing medicine by the end of 2028.
